1 / 50

CDC/James Gathany

CDC/James Gathany . COMMON COLD MOST COMMON CAUSES RHINOVIRUSES ( MEMBERS OF THE PICORNAVIRIDAE ) CORONAVIRUSES - many other viruses as well. CDC/James Gathany . Paramyxovidae (paramyovirus family) HPIV 1-4 human parainfluenza virus RSV respiratory syncytial virus hMPV

newton
Download Presentation

CDC/James Gathany

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. CDC/James Gathany

  2. COMMON COLD MOST COMMON CAUSES RHINOVIRUSES (MEMBERS OF THE PICORNAVIRIDAE) CORONAVIRUSES - many other viruses as well CDC/James Gathany

  3. Paramyxovidae (paramyovirus family) HPIV 1-4 human parainfluenza virus RSV respiratory syncytial virus hMPV human metapneumovirus Adenoviridae (adenovirus family) adenoviruses Respiratory viruses

  4. PARAMYXOVIRUSES HN/H/G glycoprotein SPIKES pleomorphic F glycoprotein SPIKES helical nucleocapsid (RNA plus NP protein) lipid bilayer membrane polymerase complex M protein

  5. PARAMYXOVIRUS FAMILYSURFACE GLYCOPROTEINS GENUS GLYCOPROTEINS TYPICAL MEMBERS PARAMYXOVIRUS SUBFAMILY Paramyxovirus HN, F HPIV1, HPIV3 Rubulavirus HN, F HPIV2, HPIV4, mumps virus Morbillivirus H, F measles virus PNEUMOVIRUS SUBFAMILY Pneumovirus G, F respiratory syncytial virus Metapneumovirus G, F human metapneumovirus

  6. Human parainfluenza virusesHPIV 1, 2, 3 and 4 • FOUR SEROTYPES • HPIV 1, 2, 3 and 4 • INFECTION • aerosol, person to person and fomites • unstable, but can survive on surfaces for a few hrs • highly contagious • susceptible to soap and water, alcohol based disinfectants, etc. • incubation 1-7 days

  7. EPIDEMIOLOGY”Iceberg phenomenon” Classical disease presentation Mild clinical disease Asymptomatic infection but infectivity (+)

  8. Human parainfluenza viruses DISEASE • usually see as upper respiratory tract infections • one of causes ‘common cold’ • coryza - inflammation nasal mucous membranes • ->congestion, headache, runny nose • fever • pharyngitis • however can be more serious as spreads down respiratory tract • croup, bronchitis, bronchiolitis, pneumonia • highest % of serious disease due to HPIV is seen in young children • second to respiratory syncytial virus in importance for lower respiratory tract disease in very young • can cause disease in adults (reinfections occur) – usually mild • reinfections in adults can sometimes be severe • especially elderly and immunocompromised – bronchiolitis, pneumonia • viremia is rare for HPIV • very rarely parotitis, meningitis, encephalitis

  9. AIRWAY NARROWING IN CROUP

  10. Human parainfluenza virusesCROUP • laryngotracheitis or laryngotracheobronchitis • primarily in young • usually <6 yrs • HPIV is most common cause of croup • other viruses also cause croup • fever, cough, hoarseness, stridor • outbreaks most often associated with HPIV1 and HPIV2 • HPIV3 – sporadic cases • humidification, racemic epinephrine, steroids (some cases)

  11. Human parainfluenza viruses • DIAGNOSIS • viral culture (shell vial cultures) http://www.lhsc.on.ca/lab/MICRO/virology/vir_cult.htm

  12. Human parainfluenza viruses DIAGNOSIS • viral culture (shell vial assays) • detect with fluorescent antibodies, hemadsorption • direct detection virus in respiratory secretions (first week of symptoms) • immunoassays or PCR • serology • rise of IgG in paired specimens or high levels IgM

  13. Human parainfluenza viruses TREATMENT • no antiviral therapy • supportive • usually self-limited • various treatments for croup

  14. Human parainfluenza viruses EPIDEMIOLOGY • restricted to humans, important and ubiquitous • most people have had all types of HPIV by 5yrs of age • reinfections throughout life • usually less severe, may be symptomatic or asymptomatic • asymptomatic infections can be infectious • usually shed for ~1 week • immunocompromised individuals with lower respiratory tract disease may shed for weeks • antigenically stable • HPIV 1 and 2 tend to be in fall • HPIV2 tends to be biennial • HPIV 3 throughout year, but especially spring and summer • HPIV 4 • less often recognized, usually milder infections • less common cause of croup, bronchiolitis

  15. Human parainfluenza viruses PREVENTION • no vaccine • passive maternal antibodies may help in first few months • hand, nose and surface hygiene

  16. Respiratory syncytial virus PARAMYXOVIRUS FAMILYSURFACE GLYCOPROTEINS GENUS GLYCOPROTEINS TYPICAL MEMBERS PARAMYXOVIRUS SUBFAMILY Paramyxovirus HN, F HPIV1, HPIV3 Rubulavirus HN, F HPIV2, HPIV4, mumps virus Morbillivirus H, F measles virus PNEUMOVIRUS SUBFAMILY Pneumovirus G, F respiratory syncytial virus Metapneumovirus G, F human metapneumovirus

  17. Respiratory syncytial virus (RSV) • 2 major strains • group A and group B (G protein differences) • multiple genotypes of each strain • currently not clear how these affect the clinical picture

  18. Respiratory syncytial virus (RSV)INFECTION • infections • aerosol, person-to-person and fomites • virus unstable, but can survive for an hour or so on hands, and on inanimate surfaces for a few hrs • easily spread (infants may have 10 million pfu/ml in nasal secretion) • virtually all children have been infected by 2yrs of age • primary infections are usually symptomatic • reinfections are common – may be symptomatic or asymptomatic • incubation period • a few days to a week • recovery takes a week or two • virus shedding • a few days to a week • 3-4 weeks in infants or immune suppressed individuals

  19. Respiratory syncytial virus (RSV) • virus confined to respiratory tract • infects respiratory epithelial cells • mucosal edema • increased mucin production • cell necrosis • obstruction by mucin/cell debris • host immune response contributes to pathology • cell mediated immunity important for recovery

  20. Respiratory syncytial virusDISEASE • common cause upper respiratory tract infections • runny nose, cough, sore throat, headache, fever, malaise, loss appetite • co-infection with bacteria usually not a problem except otitis media common • 25% of primary infections result in lower respiratory tract infections – bronchiolitis, viral pneumonia • commonest cause of bronchiolitis • if previously healthy, only a few individuals with bronchiolitis need hospitalization • re-infections usually not associated with LRT disease • but...reinfections can be associated with LRT disease • risk factors include immunosuppression, cardiopulmonary disease

  21. Respiratory syncytial virusSEVERE LRT DISEASE • risk factors for severe disease • age (especially if less than 6 months) • preterm birth • heart disease • pulmonary hypertension • lung disease of prematurity • immunodeficiency

  22. Respiratory syncytial virusTREATMENT • no specific antivirals • supportive care • hydration • assessment and management of respiratory status • ribavirin • not used routinely, may be considered in life threatening situations

  23. Respiratory syncytial virusDIAGNOSIS • rapid antigen assay • isolation (shell vial culture) • PCR • especially useful in older children and adults when viral load is usually lower and so antigen detection or viral isolation less reliable • not widely available yet • serology • usually used for epidemiology rather than diagnosis

  24. Respiratory syncytial virusEPIDEMIOLOGY • worldwide distribution • restricted to humans • US ~3000 deaths per yr • In USA usually late winter, early spring • earlier in Florida • timing helps to determine when to give prophylaxis to high-risk children • timing varies from year to year • surveillance system in US http://www.cdc.gov/Features/dsRSV/

  25. Respiratory syncytial virusPREVENTION • No vaccine • passive immunization is available for high-risk children • Hand, nose and surface hygiene • Nosocomial infections common • need to be especially rigorous when high risk patients involved • pediatric wards, neonatal units, transplantation units, etc. • gloves, gowns, masks, goggles; isolation and cohort nursing

  26. Respiratory syncytial virusPREVENTION • palivizumab (Synagis®) • humanized monoclonal antibody • for high-risk children • monthly IM injections during the RSV season • not effective in treatment of infection

  27. PARAMYXOVIRUS FAMILYSURFACE GLYCOPROTEINS GENUS GLYCOPROTEINS TYPICAL MEMBERS PARAMYXOVIRUS SUBFAMILY Paramyxovirus HN, F HPIV1, HPIV3 Rubulavirus HN, F HPIV2, HPIV4, mumps virus Morbillivirus H, F measles virus PNEUMOVIRUS SUBFAMILY Pneumovirus G, F respiratory syncytial virus Metapneumovirus G, F human metapneumovirus Human metapneumovirus (hMPV)

  28. Human metapneumovirus (hPMV) • only recently (2001) recognized • common – probably 15% of childhood colds • commercial tests only recently available • serogroup A and group B, each group has 2 subgroups based on genotype • all 4 circulate Note: can get co-infections with more than one respiratory virus

  29. Human metapneumovirus (hPMV)DISEASE • pathophysiology very similar to RSV • most children infected by age 5 • reinfections common • upper respiratory tract • common cold, croup • often complicated by otitis media • lower respiratory tract • bronchiolitis (may be involved in 10-15% cases in infants) • pneumonia • possible fatal pneumonia in bone marrow and lung transplants?

  30. Human metapneumovirus (hPMV)EPIDEMIOLOGY • worldwide • humans only source of infection • hPMV season has similar timing to RSV season • incubation period: few days to a week

  31. Human metapneumovirus (hPMV)DIAGNOSIS • antigen detection • commercially available • PCR, culture • not yet commercially available

  32. Human metapneumovirus (hPMV)TREATMENT • supportive • hydration • respiratory monitoring and management

  33. Human metapneumovirus (hPMV)PREVENTION • hand, nose and surface hygiene • similar hospital infection control practices as for RSV

  34. Adenoviruses • linear, double stranded DNA • non-enveloped • stable in environment • icosahedral • first isolated from adenoidal tissue http://www.ncbi.nlm.nih.gov/ICTVdb/ICTVdB/em_adeno.gif

  35. Adenovirus- Properties • Stable in the environment • Relatively resistant to various disinfectants • Alcohol, detergents, chlorhexidine • Stable in GI tract- can withstand low pH, bile acids and proteolytic enzymes

  36. Adenoviruses • Fiber protein – virus attachment protein • determines host cell specificiy • Virus -> nucleus • replicates DNA in nucleus • assembles nucleocapsid in nucleus • nuclear inclusion bodies • Released by cell lysis

  37. Adenoviruses • Infect mucoepithelial cells • respiratory, GI and GU tracts • Enter via epithelium, replicate and spread to lymphoid tissue • Viremia occurs • Secondary involvement of viscera

  38. Adenovirusestypes of infection • lytic • mucoepithelial cells • latent/occult • virus remains in cell – seen in lymphoid tissue • oncogenic transformation (animals only)

  39. Human Adenoviruses • Approx 51 human serotypes (1-51) • Classified into six subgroups (A-F) based on hemagglutination patterns, hexon antigenicity and sequence • members of a subgroup often cause similar spectrum of disease • enteric adenoviruses are in subgroup F (40,41)

  40. Human Adenoviruses Remaining serotypes are infrequently isolated or not clearly associated with disease. * Association with gastroenteritis not as firmly established as with types 40 and 41.

  41. Human adenoviruses TRANSMISSION • person-to-person, aerosols, fomites • respiratory secretions, tears, fecal/oral • stable in environment • not very susceptible to many disinfectants • underchlorinated swimming pools, shared towels • under sterilized medical equipment (eye exam equipment, etc)

  42. Human adenoviruses infection and shedding • incubation period few days to a couple of weeks • virus shedding usually highest during acute phase • may continue to shed at lower levels for a long time (months) • high rate of transmission to other family members (up to 50%)

  43. Human adenoviruses Timecourse - Respiratory infectionSource- Medical Microbiology- Murray, Rosenthal, Kobayshi and Pfaller

  44. Human adenovirusesDISEASE • common cold (coryza, fever, headache, malaise) • pharyngitis • bronchitis • pneumonia • diarrhea • conjunctivitis • pharyngoconjunctival fever • cystitis • rash • neurologic disease

  45. Adenovirus infections in Immunocompromised hosts • Disseminated, severe and often fatal infections • Due to new infection or reactivation of latent virus • Prolonged infections with prolonged viremia and viral shedding • Necrotizing pneumonia, hepatitis, rash, DIC, CNS involvement

  46. Human adenoviruses EPIDEMIOLOGY • human • asymptomatic infections common • reinfections common • crowding and stress can be risk factor • military basic trainees – may see in up to 10% in first week • daycare centers

  47. Human adenoviruses DIAGNOSIS • antigen testing in some body fluids • can be very rapid • cell culture (shell vial) • prolonged shedding (especially in feces) so may mean that not cause of current disease • virus isolated from URT from site associated with disease may be more relevant to current disease • not applicable for enteric types 40, 42 • PCR

  48. Human adenoviruses TREATMENT • supportive care • most infections mild • for life threatening infections (immunocompromised patient) • cidofovir

  49. Human adenoviruses PREVENTION • good hygiene • take into account that virus fairly stable • take care to thoroughly decontaminate medical equipment • adequate chlorination of swimming pools • to reduce risk pharynoconjunctival fever • use disposable or adequately sterilized items in ophthalmic practice • to reduce risk epidemic keratoconjunctivitis • no vaccine • one for military recruits no longer made

More Related